Literature DB >> 21289270

Osteoporosis medication and reduced mortality risk in elderly women and men.

Jacqueline R Center1, Dana Bliuc, Nguyen D Nguyen, Tuan V Nguyen, John A Eisman.   

Abstract

CONTEXT: Osteoporotic fractures are associated with premature mortality. Antiresorptive treatment reduces refracture but mortality reduction is unclear.
OBJECTIVE: The objective of the study was to examine the effect of osteoporosis treatment [bisphosphonates (BP), hormone therapy (HT), and calcium ± vitamin D only (CaD)] on mortality risk.
DESIGN: This was a prospective cohort study (April 1989 to May 2007).
SETTING: The study was conducted with community-dwelling elderly (aged 60+ yr) subjects in Dubbo, a semiurban city, Australia.
SUBJECTS: Subjects included 1223 and 819 women and men in the Dubbo Osteoporosis Epidemiology Study. MAIN OUTCOME MEASURE: Mortality according to treatment group was recorded.
RESULTS: There were 325 (BP, n = 106; HT, n = 77; CaD, n = 142) women and 37 men (BP, n = 15; CaD, n = 22) on treatment. In women, mortality rates were lower with BP 0.8/100 person-years (0.4, 1.4) and HT 1.2/100 person-years (0.7, 2.1) but not CaD 3.2/100 person-years (2.5, 4.1) vs. no treatment 3.5/100 person-years (3.1, 3.8). Accounting for age, fracture occurrence, comorbidities, quadriceps strength, and bone mineral density, mortality risk remained lower for women on BP [hazard ratio (HR) 0.3 (0.2, 0.6)] but not HT [HR 0.8 (0.4, 1.8)]. For 429 women with fractures, mortality risk was still reduced in the BP group [adjusted HR 0.3 (0.2, 0.7)], not accounted for by a reduction in subsequent fractures. In men, lower mortality rates were observed with BP but not CaD [BP 1.0/100 person-years (0.3, 3.9) and CaD 3.1/100 person-years (1.5, 6.6) vs. no treatment 4.3/100 person-years (3.9, 4.8)]. After adjustment, mortality was similar, although not significant [HR 0.5 (0.1, 2.0)].
CONCLUSIONS: Osteoporosis therapy appears to reduce mortality risk in women and possibly men.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289270     DOI: 10.1210/jc.2010-2730

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  62 in total

1.  Secondary fracture prevention.

Authors:  Robert A Adler
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

2.  Duration of anti-resorptive therapy for osteoporosis.

Authors:  Robert A Adler
Journal:  Endocrine       Date:  2015-10-03       Impact factor: 3.633

Review 3.  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Authors:  Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer
Journal:  J Bone Miner Res       Date:  2016-01       Impact factor: 6.741

Review 4.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

5.  Can antiosteoporotic therapy reduce mortality in MRI-proved acute osteoporotic vertebral fractures?

Authors:  Ying-Chou Chen; Fu-Mei Su; Tien-Tsai Cheng; Wei-Che Lin; Chun-Chung Lui
Journal:  J Bone Miner Metab       Date:  2015-06-04       Impact factor: 2.626

Review 6.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Authors:  Beatrice J Edwards; Andrew D Bunta; Joseph Lane; Clarita Odvina; D Sudhaker Rao; Dennis W Raisch; June M McKoy; Imran Omar; Steven M Belknap; Vishvas Garg; Allison J Hahr; Athena T Samaras; Matthew J Fisher; Dennis P West; Craig B Langman; Paula H Stern
Journal:  J Bone Joint Surg Am       Date:  2013-02-20       Impact factor: 5.284

Review 7.  Fracture mortality: associations with epidemiology and osteoporosis treatment.

Authors:  Sebastian E Sattui; Kenneth G Saag
Journal:  Nat Rev Endocrinol       Date:  2014-08-05       Impact factor: 43.330

8.  Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.

Authors:  W Brozek; B Reichardt; J Zwerina; H P Dimai; K Klaushofer; E Zwettler
Journal:  Osteoporos Int       Date:  2015-11-17       Impact factor: 4.507

Review 9.  The effect of treatments for osteoporosis on mortality.

Authors:  A Grey; M J Bolland
Journal:  Osteoporos Int       Date:  2012-10-18       Impact factor: 4.507

10.  Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis.

Authors:  Frederick Wolfe; Marcy B Bolster; Christopher M O'Connor; Kaleb Michaud; Kenneth W Lyles; Cathleen S Colón-Emeric
Journal:  J Bone Miner Res       Date:  2013-05       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.